Clinical Investigation · 2013 · 26 citations · 22 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyOncology PharmacotherapyAntineoplastic Drug ClassesOncology PharmacologyOral Anticancer AgentsPharmacokinetics Of Anticancer DrugsAnticancer ActivityChemotherapy-related Oral ToxicityPhase I Clinical TrialsTaxane ChemotherapyTaxane TherapyTaxane-based Chemotherapy
The oral taxanes are analogues of existing taxanes with a possible broad range of antitumor activity. They also have the potential advantages of ease of administration, better efficacy and lesser toxicity than currently available taxanes. These drugs have been used in several Phase I clinical trials, the methodology and results of which will be reviewed here.
22
IDN5109, a taxane with oral bioavailability and potent antitumor activity.
Maria Nicoletti, Tina Colombo, Cosmo Rossi et al. · PubMed · 2000 · 74 citations
MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.
Deepak Sampath, Carolyn Discafani, Frank Loganzo et al. · PubMed · 2003 · 66 citations
Medicine, Oncology, Pharmacology +17
Preclinical pharmacology of BMS-275183, an orally active taxane.
William C. Rose, Byron H. Long, Craig R. Fairchild et al. · PubMed · 2001 · 61 citations
Medicine, Oncology, Pharmacology +15